Total Payments
$817.34
2024 Payments
$44.62
Companies
11
Transactions
17
Medicare Patients
821
Medicare Billing
$121,377
Payment Breakdown by Category
Consulting$400.00 (48.9%)
Food & Beverage$207.35 (25.4%)
Research$150.00 (18.4%)
Education$59.99 (7.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $400.00 | 1 | 48.9% |
| Food and Beverage | $207.35 | 14 | 25.4% |
| Unspecified | $150.00 | 1 | 18.4% |
| Education | $59.99 | 1 | 7.3% |
Payments by Type
General
$667.34
16 transactions
Research
$150.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $415.00 | 2 | $0 (2019) |
| Indivior Inc. | $150.00 | 1 | $0 (2020) |
| Pharmacyclics LLC, An AbbVie Company | $71.05 | 2 | $0 (2017) |
| Orexo US, Inc. | $42.65 | 3 | $0 (2022) |
| GlaxoSmithKline, LLC. | $36.72 | 3 | $0 (2017) |
| Braeburn Inc. | $27.26 | 1 | $0 (2024) |
| Novo Nordisk Inc | $24.27 | 1 | $0 (2023) |
| TAIHO ONCOLOGY, INC. | $17.36 | 1 | $0 (2024) |
| Helsinn Therapeutics (U.S.), Inc. | $11.69 | 1 | $0 (2017) |
| Medtronic MiniMed, Inc. | $10.73 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $44.62 | 2 | Braeburn Inc. ($27.26) |
| 2023 | $24.27 | 1 | Novo Nordisk Inc ($24.27) |
| 2022 | $13.34 | 1 | Orexo US, Inc. ($13.34) |
| 2021 | $15.77 | 1 | Orexo US, Inc. ($15.77) |
| 2020 | $163.54 | 2 | Indivior Inc. ($150.00) |
| 2019 | $15.00 | 1 | AstraZeneca Pharmaceuticals LP ($15.00) |
| 2018 | $400.00 | 1 | AstraZeneca Pharmaceuticals LP ($400.00) |
| 2017 | $140.80 | 8 | Pharmacyclics LLC, An AbbVie Company ($71.05) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/09/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $27.26 | General |
| Category: Opioid Use Disorder | ||||||
| 02/23/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: Oncology | ||||||
| 08/21/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $24.27 | General |
| 04/22/2022 | Orexo US, Inc. | — | Food and Beverage | Cash or cash equivalent | $13.34 | General |
| 08/19/2021 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $15.77 | General |
| Category: Addiction Medicine | ||||||
| 11/18/2020 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $13.54 | General |
| Category: Addiction Medicine | ||||||
| 07/21/2020 | Indivior Inc. | BUPRENORPHINE AND NALOXONE (Drug), SUBOXONE | — | Cash or cash equivalent | $150.00 | Research |
| Study: Quantitative Testing of Prescriber/Pharmacist Knowledge, Attitudes and Behavior about SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) or the Authorized Generic of SUBOXONE Sublingual Film (CIII) Safety and Use Information • Category: OUD | ||||||
| 04/17/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 01/23/2018 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: Oncology | ||||||
| 11/01/2017 | Helsinn Therapeutics (U.S.), Inc. | ALOXI (Drug), ZYKADIA, AKYNZEO | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2017 | Lexicon Pharmaceuticals, Inc. | Xermelo (Drug) | Food and Beverage | In-kind items and services | $10.61 | General |
| Category: Carcinoid Syndrome Diarrhea | ||||||
| 09/26/2017 | Medtronic MiniMed, Inc. | iPro2 (Device) | Food and Beverage | In-kind items and services | $10.73 | General |
| Category: Continuous Glucose Monitoring | ||||||
| 08/25/2017 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Education | In-kind items and services | $59.99 | General |
| Category: Oncology | ||||||
| 05/22/2017 | GlaxoSmithKline, LLC. | ANORO (Drug) | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: RESPIRATORY | ||||||
| 05/03/2017 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $11.06 | General |
| Category: Oncology | ||||||
| 04/06/2017 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $11.44 | General |
| Category: RESPIRATORY | ||||||
| 02/20/2017 | GlaxoSmithKline, LLC. | ANORO (Drug) | Food and Beverage | In-kind items and services | $12.56 | General |
| Category: RESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Quantitative Testing of Prescriber/Pharmacist Knowledge, Attitudes and Behavior about SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) or the Authorized Generic of SUBOXONE Sublingual Film (CIII) Safety and Use Information | Indivior Inc. | $150.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 150 | 312 | $56,529 | $22,445 |
| 2022 | 7 | 199 | 414 | $73,946 | $29,736 |
| 2021 | 6 | 211 | 509 | $77,370 | $32,678 |
| 2020 | 7 | 261 | 623 | $101,425 | $36,517 |
Total Patients
821
Total Services
1,858
Medicare Billing
$121,377
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 78 | 176 | $41,362 | $15,258 | 36.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 48 | 48 | $12,857 | $6,301 | 49.0% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 12 | 66 | $1,980 | $815.10 | 41.2% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 12 | 22 | $330.00 | $70.62 | 21.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 68 | 178 | $40,050 | $15,421 | 38.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 47 | 47 | $12,455 | $6,344 | 50.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 33 | 40 | $12,533 | $4,477 | 35.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $5,368 | $2,023 | 37.7% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2022 | 17 | 99 | $2,970 | $1,233 | 41.5% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 11 | 18 | $270.00 | $172.76 | 64.0% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 11 | 20 | $300.00 | $64.79 | 21.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 87 | 246 | $55,525 | $22,467 | 40.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 56 | 56 | $14,840 | $7,725 | 52.1% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2021 | 24 | 135 | $4,050 | $1,701 | 42.0% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 13 | 15 | $2,100 | $418.10 | 19.9% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 15 | 28 | $420.00 | $271.88 | 64.7% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2021 | 16 | 29 | $435.00 | $95.12 | 21.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 109 | 323 | $72,675 | $25,134 | 34.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 50 | 50 | $13,310 | $6,031 | 45.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 14 | 14 | $5,950 | $1,966 | 33.0% |
| 80305 | Testing for presence of drug | Office | 2020 | 25 | 129 | $3,870 | $1,614 | 41.7% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 28 | 45 | $4,690 | $1,426 | 30.4% |
| 83036 | Hemoglobin a1c level | Office | 2020 | 16 | 23 | $345.00 | $221.43 | 64.2% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2020 | 19 | 39 | $585.00 | $126.38 | 21.6% |
About David Stoll
David Stoll is a Hematology & Oncology healthcare provider based in Woonsocket, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/28/2005. The National Provider Identifier (NPI) number assigned to this provider is 1114927431.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, David Stoll has received a total of $817.34 in payments from pharmaceutical and medical device companies, with $44.62 received in 2024. These payments were reported across 17 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($400.00).
As a Medicare-enrolled provider, Stoll has provided services to 821 Medicare beneficiaries, totaling 1,858 services with total Medicare billing of $121,377. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Woonsocket, RI
- Active Since 07/28/2005
- Last Updated 06/09/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1114927431
Products in Payments
- TAGRISSO (Drug) $400.00
- BUPRENORPHINE AND NALOXONE (Drug) $150.00
- Imbruvica (Drug) $71.05
- Zubsolv (Drug) $29.31
- BRIXADI (Drug) $27.26
- ANORO (Drug) $25.28
- LONSURF (Drug) $17.36
- ALOXI (Drug) $11.69
- BREO (Drug) $11.44
- iPro2 (Device) $10.73
- Xermelo (Drug) $10.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.